Ark Granted Patent in Europe for Trinam®
Ark Therapeutics Group plc announced that it has been issued with a patent by the European Patent Office for Trinam®, its novel therapy to prevent blood vessels blocking after vascular graft access surgery. Subject to the payment of renewal fees, this patent can be maintained until at least 2016.
Trinam® is a combination of a Vascular Endothelial Growth Factor (VEGF) gene in an adenoviral vector and Ark's biodegradable collagen collar local delivery device (EG001). The initial target market for Trinam® is haemodialysis access graft surgery, a treatment for kidney failure patients where a plastic tube is grafted between blood vessels in the forearm to enable regular blood filtration. At the end of the access graft surgery procedure, the EG001 delivery device is fitted around the outside of the vein where it had been joined to the access graft. The VEGF gene in solution is then injected into the reservoir formed between the delivery device and the blood vessel, from where it passes into the blood vessel wall, transfecting the smooth muscles cells in the wall - a process known as adventitial transfection. This unique method of administration allows Trinam® to be localised to the target site where the therapy is needed.
Preclinical studies have demonstrated a significant effect in preventing intimal hyperplasia and successful adventitial gene transfer. Trinam® is currently in Phase II clinical trials in the USA. The Phase II ascending dose study in up to 20 patients is designed to examine the efficacy and safety of Trinam® in patients undergoing haemodialysis access graft surgery.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Nano Ruffles in Brain Matter - Researchers decipher the role of nanostructures around brain cells in central nervous system function
Carl_Freiherr_von_Rokitansky
Actelion announces change in its management structure - Otto Schwarz appointed Chief Operating Officer
EPO for the Brain - Engineered Moss produces human hormone without doping activity
ProtAffin AG granted patent in EU for CellJammer discovery technology - Novel technology enables development of a new class of biopharmaceuticals

CSIC researchers find the role of a protein in the regulation of synapse formation - The work raises the need for a balance between the Pinkman protein and the sHSPs proteins during the development of the nervous system for its correct formation
Affymetrix Selected to Genotype More Than 9,000 Framingham Heart Study Samples - SHARE Project to Help Identify Genetic Variants Associated With Heart, Lung, Blood and Sleep Disorders

New app calculates corona infection risk in rooms - Size of aerosol droplets that virus carriers release strongly influences infectivity
Northern_Norway_Pharmaceutical_Trust
